Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation (NASDAQ: IRMD) is focused on MRI-compatible medical devices, and its news flow reflects that specialization. The company regularly issues press releases describing its financial results, product clearances, board changes, and capital allocation decisions. Investors and observers following IRMD news can see how its non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems perform in the marketplace and how management communicates about growth and operations.
Recent news has highlighted record quarterly revenue over multiple consecutive quarters, along with updates on gross margins, domestic and international sales mix, and cash flow from operations. The company also reports on its use of non-GAAP financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, and free cash flow, explaining how these metrics relate to its GAAP results. Dividend announcements, including regular quarterly cash dividends and a special cash dividend, are another recurring theme in iRadimed’s news releases.
Product and regulatory developments are also covered in detail. For example, iRadimed announced FDA 510(k) clearance for its MRidium 3870 IV Infusion Pump System, described as a next-generation MRI-compatible infusion pump with a non-magnetic ultrasonic motor, non-interfering RF emissions, and advanced safety and user interface features. News items also describe the capabilities of the 3880 MRI-compatible patient vital signs monitoring system, which operates in magnetic fields up to 30,000 gauss and is designed to travel with patients between critical care units and MRI suites.
Governance and recognition-related news includes disclosures about changes in the Board of Directors and iRadimed’s inclusion in TIME’s list of America’s Growth Leaders for 2026. Conference participation announcements and earnings call schedules provide additional context for those who want to follow company presentations and management commentary. For anyone tracking IRMD, this news feed offers a consolidated view of its financial performance, product milestones, governance updates, and other corporate developments.
Iradimed Corporation (NASDAQ: IRMD) reported Q1 2021 revenue of $9.2 million, up from $8.7 million in Q1 2020. GAAP diluted EPS was $0.11 compared to $0.14 the previous year, primarily due to a $0.4 million tax expense. Non-GAAP diluted EPS was $0.13, down from $0.18. The company noted a 32% increase in IV pump revenue and 112% growth in income before taxes. Cash and investments totaled $52.7 million as of March 31, 2021. Iradimed refrained from providing financial guidance due to ongoing COVID-19 uncertainties.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its Q1 2021 financial results on April 30, 2021, before market open. A conference call will follow at 11:00 a.m. ET for management to discuss these results and answer questions. Interested parties can listen by calling 1-844-413-1781 domestically or 1-716-247-5767 internationally, using reservation code 8386999. The call will also be streamed online and a recording will be available on the company’s website for 90 days post-call.
IRADIMED CORPORATION (NASDAQ: IRMD) reported fourth quarter 2020 revenue of $8.5 million, a decline from $10.9 million in Q4 2019. The company's GAAP diluted EPS was $0.05, down from $0.26 year-over-year. Non-GAAP diluted EPS was $0.07, compared to $0.30 in 2019. Total revenue for 2020 was $31.7 million, a decrease from $38.5 million in 2019. As of December 31, 2020, cash and investments totaled $52.0 million. The company remains cautious about the first half of 2021 due to ongoing uncertainties related to COVID-19.
IRADIMED CORPORATION (NASDAQ: IRMD) is set to release its Q4 2020 financial results on February 4, before market opens. A conference call will follow at 11:00 AM ET to discuss results and answer questions. Interested parties can join via phone or listen online. The company specializes in MRI-compatible medical devices, including the patented MRidium® IV infusion pump and the 3880 vital signs monitoring system, both designed to enhance patient safety during MRI procedures.
iRadimed Corporation (NASDAQ: IRMD) reported Q3 2020 revenue of $7.7 million, down from $10.0 million in Q3 2019. Net income fell to $1.1 million or $0.09 per diluted share, compared to $2.5 million or $0.20 for Q3 2019. For the first nine months, revenue declined to $23.2 million from $27.6 million in 2019, with net income of $0.7 million or $0.06 per diluted share. The company held $49.9 million in cash and investments as of September 30, 2020. Financial guidance remains unavailable due to uncertainties from the COVID-19 pandemic.
IRADIMED CORPORATION (NASDAQ: IRMD) will disclose its 2020 third-quarter financial results on October 30, before market opening. Management will host a conference call at 11:00 a.m. ET to discuss the results and address queries. Interested parties can join the call by dialing designated numbers or listen online. IRADIMED specializes in MRI-compatible medical devices, being the sole provider of a non-magnetic IV infusion pump system, which ensures safety during MRI procedures, particularly for critically ill patients and children.
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its second quarter financial results for 2020 on July 30, 2020, before market open. Management will host a conference call at 11:00 a.m. ET that day to discuss the results and answer questions. Interested parties can join the call by dialing 1-844-413-1781 (domestic) or 1-716-247-5767 (international) with reservation code 8281889. The call will be accessible online and a recording will be available on their website for 90 days thereafter.
Summary not available.